These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 35665579)

  • 21. Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension.
    Gaine S; Chin K; Coghlan G; Channick R; Di Scala L; Galiè N; Ghofrani HA; Lang IM; McLaughlin V; Preiss R; Rubin LJ; Simonneau G; Sitbon O; Tapson VF; Hoeper MM
    Eur Respir J; 2017 Aug; 50(2):. PubMed ID: 28818881
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enrichment Benefits of Risk Algorithms for Pulmonary Arterial Hypertension Clinical Trials.
    Scott JV; Garnett CE; Kanwar MK; Stockbridge NL; Benza RL
    Am J Respir Crit Care Med; 2021 Mar; 203(6):726-736. PubMed ID: 32937078
    [No Abstract]   [Full Text] [Related]  

  • 23. Selexipag: A Review in Pulmonary Arterial Hypertension.
    Duggan ST; Keam SJ; Burness CB
    Am J Cardiovasc Drugs; 2017 Feb; 17(1):73-80. PubMed ID: 27988834
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selexipag for the treatment of pulmonary arterial hypertension.
    Sharma K
    Expert Rev Respir Med; 2016; 10(1):1-3. PubMed ID: 26567613
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selexipag treatment in patients with systemic sclerosis-associated pulmonary arterial hypertension in clinical practice, a case series.
    Lemmers JM; Fretheim H; Knaapen HK; van den Hoogen FH; van Haren-Willems JH; Duijnhouwer AL; van Dijk AP; van den Ende CH; Hoffmann-Vold AM; Vonk MC
    J Scleroderma Relat Disord; 2020 Oct; 5(3):NP7-NP11. PubMed ID: 35382522
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selexipag for the treatment of children with pulmonary arterial hypertension: First multicenter experience in drug safety and efficacy.
    Hansmann G; Meinel K; Bukova M; Chouvarine P; Wåhlander H; Koestenberger M;
    J Heart Lung Transplant; 2020 Jul; 39(7):695-706. PubMed ID: 32362477
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Temporarily switching from oral to intravenous selexipag in patients with pulmonary arterial hypertension: safety, tolerability, and pharmacokinetic results from an open-label, phase III study.
    Klose H; Chin KM; Ewert R; Gall H; Parambil J; Poch D; Seyfarth HJ; Axelsen LN; Hsu Schmitz SF; Stein C; Preston IR
    Respir Res; 2021 Feb; 22(1):34. PubMed ID: 33536021
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study.
    Frost A; Janmohamed M; Fritz JS; McConnell JW; Poch D; Fortin TA; Miller CE; Chin KM; Fisher M; Eggert M; McEvoy C; Benza RL; Farber HW; Kim NH; Pfister T; Shiraga Y; McLaughlin V
    J Heart Lung Transplant; 2019 Jan; 38(1):43-50. PubMed ID: 30391194
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Population Modeling of Selexipag Pharmacokinetics and Clinical Response Parameters in Patients With Pulmonary Arterial Hypertension.
    Krause A; Machacek M; Lott D; Hurst N; Bruderer S; Dingemanse J
    CPT Pharmacometrics Syst Pharmacol; 2017 Jul; 6(7):477-485. PubMed ID: 28556581
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-Life Experience with Selexipag as an Add-On Therapy to Oral Combination Therapy in Patients with Pulmonary Arterial or Distal Chronic Thromboembolic Pulmonary Hypertension: A Retrospective Analysis.
    Berlier C; Schwarz EI; Saxer S; Lichtblau M; Ulrich S
    Lung; 2019 Jun; 197(3):353-360. PubMed ID: 30963265
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selexipag: First Global Approval.
    Scott LJ
    Drugs; 2016 Mar; 76(3):413-8. PubMed ID: 26846322
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Contemporary use of Selexipag in pulmonary arterial hypertension associated with congenital heart disease: a case series.
    Blissett S; Blusztein D; Mahadevan VS
    Eur Heart J Case Rep; 2020 Dec; 4(6):1-7. PubMed ID: 33442633
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Case Report of a Patient With Pulmonary Arterial Hypertension Transitioned From Inhaled Iloprost to Selexipag.
    Verlinden NJ; Walter C; Raina A; Benza RL
    J Pharm Pract; 2021 Dec; 34(6):980-983. PubMed ID: 32912036
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Baseline history of patients using selexipag for pulmonary arterial hypertension.
    Highland KB; Hull M; Pruett J; Elliott C; Tsang Y; Drake W
    Ther Adv Respir Dis; 2019; 13():1753466619843774. PubMed ID: 30983530
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safe and successful transition from oral selexipag to subcutaneous treprostinil in a patient with idiopathic pulmonary arterial hypertension treated with triple combination therapy.
    Adachi S; Nishiyama I; Yasuda K; Yoshida M; Nakano Y; Kondo T; Murohara T
    J Cardiol Cases; 2022 Jul; 26(1):42-45. PubMed ID: 35923524
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selexipag for the treatment of pulmonary arterial hypertension.
    Richter MJ; Gall H; Grimminger J; Grimminger F; Ghofrani HA
    Expert Opin Pharmacother; 2016 Sep; 17(13):1825-34. PubMed ID: 27467883
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and Safety of an Orally Administered Selective Prostacyclin Receptor Agonist, Selexipag, in Japanese Patients With Pulmonary Arterial Hypertension.
    Tanabe N; Ikeda S; Tahara N; Fukuda K; Hatano M; Ito H; Nakayama T; Anzai T; Hashimoto A; Inoue T; Kajinami K; Kihara Y; Kinoshita H; Kuwahara K; Murohara T; Okazaki O; Sakai S; Satoh T; Takeda Y; Takeishi Y; Taniguchi M; Watanabe H; Yamamoto T; Yamauchi-Takihara K; Yoshioka K; Sasayama S
    Circ J; 2017 Aug; 81(9):1360-1367. PubMed ID: 28420826
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The selective PGI2 receptor agonist selexipag ameliorates Sugen 5416/hypoxia-induced pulmonary arterial hypertension in rats.
    Honda Y; Kosugi K; Fuchikami C; Kuramoto K; Numakura Y; Kuwano K
    PLoS One; 2020; 15(10):e0240692. PubMed ID: 33057388
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selexipag, an Oral Prostacyclin-Receptor Agonist for Pulmonary Arterial Hypertension.
    Baker WL; Darsaklis K; Singhvi A; Salerno EL
    Ann Pharmacother; 2017 Jun; 51(6):488-495. PubMed ID: 28478717
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rapid transition from oral selexipag to parenteral treprostinil in a patient with mixed-etiology pulmonary hypertension.
    Radosevich JJ; DeChristopher A; Irandost M; Fann J; Feldman J
    Am J Health Syst Pharm; 2020 Jul; 77(15):1208-1212. PubMed ID: 32620953
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.